OncoMatch/Clinical Trials/NCT03753243
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Is NCT03753243 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Enzalutamide for prostate cancer.
Treatment: Pembrolizumab · Enzalutamide — Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Demonstrate adequate organ function, all screening labs should be performed within 30 days of treatment initiation.
Kidney function
Demonstrate adequate organ function, all screening labs should be performed within 30 days of treatment initiation.
Liver function
Demonstrate adequate organ function, all screening labs should be performed within 30 days of treatment initiation.
Demonstrate adequate organ function, all screening labs should be performed within 30 days of treatment initiation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- VA Portland Healthcare System · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify